{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-038703","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.389415+00:00","generated_at":"2026-05-24T20:38:50.938557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma reports year-end 2024 cash of $75.1M; Phase 3 topline data due Q3 2025","bullets":["Cash, equivalents and investments $75.1M as of Dec 31, 2024; raised ~$18.8M via ATM after quarter-end.","Phase 3 EFZO-FIT enrollment complete (268 patients); topline pulmonary sarcoidosis data expected Q3 2025.","Fourth positive DSMB review; FDA meeting finalized SAP on steroid reduction endpoint.","Phase 2 EFZO-CONNECT interim data for scleroderma-ILD expected Q2 2025.","R&D expenses $54.4M, G&A $13.8M for FY2024; cash runway extends one year past Phase 3 readout."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-038703","json":"https://secwatch.observer/filing/0000950170-25-038703.json","markdown":"https://secwatch.observer/filing/0000950170-25-038703.md","text":"https://secwatch.observer/filing/0000950170-25-038703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/0000950170-25-038703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/atyr-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T20:38:50.938557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}